Shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) dropped 0% during trading on Thursday . The company traded as low as $1.53 and last traded at $1.59. Approximately 1,534,648 shares traded hands during trading, a decline of 53% from the average daily volume of 3,284,780 shares. The stock had previously closed at $1.59.

Separately, Maxim Group started coverage on Interpace Diagnostics Group in a research note on Tuesday, August 15th. They issued a “buy” rating and a $5.00 price target on the stock.

The stock has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.79. The firm’s market cap is $35.24 million.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings results on Thursday, August 10th. The business services provider reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $3.86 million for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Susquehanna International Group LLP purchased a new stake in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned approximately 3.84% of Interpace Diagnostics Group as of its most recent SEC filing. Hedge funds and other institutional investors own 7.58% of the company’s stock.

WARNING: “Interpace Diagnostics Group, Inc. (IDXG) Shares Down 0%” was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.